Role of BRAF mutation in the treatment for melanoma

http://youtu.be/2HkvgOOwgM4 At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, from Universitätsklinikum Essen, Essen, Germany, discusses advances in the biological understanding of BRAF-mutant melanoma, which involves the constitutive activation of the MAPK pathway and have led to the development of new targeted therapies for patients with metastatic disease.